Significant bleeding disorder;
Active bleeding disorder in the past  months.
History of a bleeding disorder
History of significant bleeding disorder unrelated to cancer
history of bleeding disorder
History of significant bleeding disorder unrelated to chronic myelogenous leukemia (CML), including:\r\n* Diagnosed congenital bleeding disorders (e.g. von Willebrands disease) \r\n* Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor VII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrands disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\r\n* Ongoing or recent (=<  months) significant gastrointestinal bleeding
Evidence of active bleeding or bleeding disorder
History of significant bleeding disorder unrelated to cancer, including: \r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrands disease) \r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) \r\n* History of gastrointestinal (GI) bleeding within one year
History of significant bleeding disorder unrelated to cancer, including: ) diagnosed congenital bleeding disorders (e.g., von Willebrands disease); ) diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of screening visit; ) history of gastrointestinal (GI) bleeding within  months of screening visit requiring >=  units packed red blood cells.
History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrands disease); diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
Evidence or history of bleeding disorder.
History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrands disease, diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies, or ongoing or recent (=<  months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including: Diagnosed congenital bleeding disorders (e.g., von Willebrands disease); and diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
Has a bleeding disorder or a screening platelet count < /L.
History of clinically significant bleeding or known platelet or coagulation disorder
Anti-coagulant therapy, bleeding or clotting disorder
History of significant congenital or acquired bleeding disorder unrelated to cancer
Documented or known bleeding disorder.
Have a significant bleeding disorder or vasculitis or had a Grade ? bleeding episode within  weeks prior to enrollment.
Any history of significant bleeding disorder unrelated to cancer, including any congenital bleeding disorder or any acquired bleeding disorder within one year of start of study
Patients meeting the following criteria are not eligible unless cleared by cardiology: \r\n* Uncontrolled angina within  months\r\n* Diagnosed or suspected congenital long QT syndrome\r\n* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)\r\n* Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>  msec) \r\n* History of significant bleeding disorder unrelated to cancer, including: \r\n** Diagnosed congenital bleeding disorders (e.g., von Willebrands disease) \r\n** Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Documented or known bleeding disorder.
Patients with history of clinically significant bleeding disorder
Documented or known bleeding disorder.
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrands disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrands disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\r\n* Ongoing or recent (=<  months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including diagnosed congenital bleeding disorders (e.g., von Willebrands disease), or diagnosed acquired bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies)
Patients with history of bleeding disorder or with history of spontaneous haemorrhage tumour
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder or uncontrolled seizures
Subject has an underlying bleeding disorder
Have active uncontrolled bleeding or a known bleeding disorder
History or evidence of bleeding disorder or active clinically significant bleeding requiring medical intervention.
History of significant congenital or acquired bleeding disorder unrelated to cancer
Active bleeding disorder or other history of significant bleeding episodes within  days before study entry
History of significant bleeding disorder unrelated to cancer, including diagnosed congenital bleeding disorders (e.g., von Willebrands disease)
The participant has a significant bleeding disorder or vasculitis.
Has active bleeding disorder or other history of significant bleeding episodes within  days of randomization.
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrands disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Patients with an uncontrolled bleeding disorder
History of significant congenital or acquired bleeding disorder
History of significant congenital or acquired bleeding disorder unrelated to cancer
Patient has a bleeding disorder or a screening platelet count </L.
Subjects with uncontrolled bleeding disorder which cannot be controlled with anticoagulants
History of significant bleeding disorder unrelated to cancer
Concurrent medical conditions or injury which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), history of human immunodeficiency virus (HIV)-positive, or active or chronic hepatitis C and/or B infection
Concurrent medical conditions which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), human immunodeficiency virus (HIV)-positive
PART B: History of clinically significant bleeding disorder
History of significant bleeding disorder unrelated to cancer, including: congenital bleeding disorders (e.g, von Willebrand's disease), acquired bleeding disorder within the past  months (e.g, acquired anti-factor VIII antibodies, including any ongoing or recent less than or equal to  months), significant gastrointestinal bleeding, or use of oral anticoagulant therapy
History of significant congenital or acquired bleeding disorder unrelated to cancer
Documented or known clinically significant bleeding disorder.
Known presence of a significant congenital or acquired bleeding disorder unrelated to cancer
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrands disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\r\n* Ongoing or recent (=<  months) significant gastrointestinal bleeding
History of significant congenital or acquired bleeding disorder unrelated to cancer
Previous history of primary platelet disorder or bleeding disorder
Have a significant bleeding disorder unrelated to CML or Ph+ALL
Bleeding disorder
History of underlying bleeding disorder, such as hemophilia
History of significant bleeding disorder unrelated to cancer, including:  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)  Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Known systemic bleeding or platelet disorder
Suffering from a known bleeding disorder.
History of significant congenital or acquired bleeding disorder unrelated to cancer
Evidence or history of any bleeding or coagulation disorder
Clinically significant coagulopathy or bleeding disorder.
PART I: History of bleeding disorder
PART II: History of bleeding disorder
Uncorrected bleeding disorder.
History of significant bleeding disorder unrelated to cancer, including:
Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of Screening visit
History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrands disease), diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrands disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Known bleeding disorder per patient reported history
Uncontrolled hereditary or acquired thrombotic or bleeding disorder.
Patients must not have a severe bleeding disorder
Congenital bleeding disorder or predisposition to priapism that is contraindicative to vacuum constriction\r\ndevices (VCD) use
Bleeding disorder
History of significant bleeding disorder unrelated to CML
Known presence of significant congenital or acquired bleeding disorder unrelated to cancer
